Indications and Effectiveness

Indications

EXOGEN® system is the only FDA-approved device indicated to accelerate healing for indicated* fresh tibia and radius fractures, and has been indicated for treatment of established non-union fractures, excluding skull and vertebra. EXOGEN has not been tested in pregnant or skeletally immature patients.

Proven effectiveness

EXOGEN accelerates the healing of indicated* fresh fractures by 38%,2,3 resolves 86% of non-unions,4 and is effective in a wide range of patients and fractures:

  • Smokers12
  • Advanced age13
  • Deep or superficial fractures10
  • Infected non-unions14
  • Atrophic non-unions15
  • Hypertrophic non-unions15
  • Non-unions with metal implants6

Common fractures at risk for non-unions

In many cases, EXOGEN may prevent the need for further surgery.4

EXOGEN non-union heal rates

Heal rates based on fracture age of 91–180 days.

*Includes metacarpal, carpal and hamate
**Includes talus, calcaneus, tarsal navicular, cuboid and cuneiform

  • High treatment
    compliance21
  • +
  • Proven clinical
    effectiveness2-4
  • > >
  • Successful fracture
    healing outcomes